Illuminating liver fibrosis with vitamin D

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 1, 2014, Pages 5-8

  Firrincieli, D ^a,b   Braescu, T ^a,b   Housset, C ^a,b,c   Chignard, N ^a,b  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔpital Saint Antoine   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; GENE REGULATORY NETWORKS; LIVER; MALE; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION;

EID: 84893970566     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.10.004     Document Type: Article

References (42)

1. Lemoinne S., Cadoret A., El Mourabit H., Thabut D., Housset C. Origins and functions of liver myofibroblasts. Biochim Biophys Acta 2013, 1832:948-954.
2. Kisseleva T., Brenner D.A. Inactivation of myofibroblasts during regression of liver fibrosis. Cell Cycle 2013, 12:381-382.
3. Ding N., Yu R.T., Subramaniam N., Sherman M.H., Wilson C., Rao R., et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013, 153:601-613.
4. Miyahara T., Schrum L., Rippe R., Xiong S., Yee H.F., Motomura K., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000, 275:35715-35722.
5. Marra F., Efsen E., Romanelli R.G., Caligiuri A., Pastacaldi S., Batignani G., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000, 119:466-478.
6. Hazra S., Xiong S., Wang J., Rippe R.A., Krishna V., Chatterjee K., et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 2004, 279:11392-11401.
7. Galli A., Crabb D.W., Ceni E., Salzano R., Mello T., Svegliati-Baroni G., et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002, 122:1924-1940.
8. Beaven S.W., Wroblewski K., Wang J., Hong C., Bensinger S., Tsukamoto H., et al. Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology 2011, 140:1052-1062.
9. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004, 127:1497-1512.
10. Fickert P., Fuchsbichler A., Moustafa T., Wagner M., Zollner G., Halilbasic E., et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 2009, 175:2392-2405.
11. Abramovitch S., Dahan-Bachar L., Sharvit E., Weisman Y., Tov A.B., Brazowski E., et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011.
12. Hughes M.R., Malloy P.J., Kieback D.G., Kesterson R.A., Pike J.W., Feldman D., et al. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 1988, 242:1702-1705.
13. Moore D.D., Kato S., Xie W., Mangelsdorf D.J., Schmidt D.R., Xiao R., et al. International Union of Pharmacology, LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol Rev 2006, 58:742-759.
14. Bookout A.L., Jeong Y., Downes M., Yu R.T., Evans R.M., Mangelsdorf D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006, 126:789-799.
15. Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer H.F., et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008, 29:726-776.
16. Gascon-Barre M., Demers C., Mirshahi A., Neron S., Zalzal S., Nanci A. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 2003, 37:1034-1042.
17. Zuniga S., Firrincieli D., Housset C., Chignard N. Vitamin D and the vitamin D receptor in liver pathophysiology. Clin Res Hepatol Gastroenterol 2011, 35:295-302.
18. Fan L., Tu X., Zhu Y., Zhou L., Pfeiffer T., Feltens R., et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol 2005, 20:249-255.
19. Halmos B., Szalay F., Cserniczky T., Nemesanszky E., Lakatos P., Barlage S., et al. Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype polymorphism in a Hungarian population. Dig Dis Sci 2000, 45:1091-1095.
20. Lakatos L.P., Bajnok E., Hegedus D., Toth T., Lakatos P., Szalay F. Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2002, 14:733-740.
21. Tanaka A., Nezu S., Uegaki S., Kikuchi K., Shibuya A., Miyakawa H., et al. Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. J Hepatol 2009, 50:1202-1209.
22. Vogel A., Strassburg C.P., Manns M.P. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002, 35:126-131.
23. Barchetta I., Carotti S., Labbadia G., Gentilucci U.V., Muda A.O., Angelico F., et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012, 56:2180-2187.
24. Petta S., Camma C., Scazzone C., Tripodo C., Di Marco V., Bono A., et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010, 51:1158-1167.
25. Terrier B., Carrat F., Geri G., Pol S., Piroth L., Halfon P., et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 2011, 55:756-761.
26. Tan X., Li Y., Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006, 17:3382-3393.
27. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003, 112:1776-1784.
28. Jones D.E. Pathogenesis of primary biliary cirrhosis. Gut 2007, 56:1615-1624.
29. Robertson H., Kirby J.A., Yip W.W., Jones D.E., Burt A.D. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 2007, 45:977-981.
30. Chu A.S., Diaz R., Hui J.J., Yanger K., Zong Y., Alpini G., et al. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 2011, 53:1685-1695.
31. Scholten D., Osterreicher C.H., Scholten A., Iwaisako K., Gu G., Brenner D.A., et al. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 2010, 139:987-998.
32. Firrincieli D., Zuniga S., Rey C., Wendum D., Lasnier E., Rainteau D., et al. Vitamin D nuclear receptor deficiency promotes cholestatic liver injury by disruption of biliary epithelial cell junctions in mice. Hepatology 2013, 58:1401-1412.
33. D'Aldebert E., Biyeyeme Bi Mve M.J., Mergey M., Wendum D., Firrincieli D., Coilly A., et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 2009, 136:1435-1443.
34. Honjo Y., Sasaki S., Kobayashi Y., Misawa H., Nakamura H. 1,25-dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. J Endocrinol 2006, 188:635-643.
35. Jiang W., Miyamoto T., Kakizawa T., Nishio S.I., Oiwa A., Takeda T., et al. Inhibition of LXRalpha signaling by vitamin D receptor: possible role of VDR in bile acid synthesis. Biochem Biophys Res Commun 2006, 351:176-184.
36. Yanagisawa J., Yanagi Y., Masuhiro Y., Suzawa M., Watanabe M., Kashiwagi K., et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999, 283:1317-1321.
37. Inoue K., Matsui I., Hamano T., Fujii N., Shimomura A., Nakano C., et al. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3. Lab Invest 2012, 92:1686-1697.
38. Subramaniam N., Leong G.M., Cock T.A., Flanagan J.L., Fong C., Eisman J.A., et al. Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001, 276:15741-15746.
39. Zeybel M., Mann D.A., Mann J. Epigenetic modifications as new targets for liver disease therapies. J Hepatol 2013, dx.doi.org/10.1016/j.jhep.2013.05.039.
40. Mann J., Chu D.C., Maxwell A., Oakley F., Zhu N.L., Tsukamoto H., et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010, 138. 705-14, 14 e1-4.
41. Alvarez-Diaz S., Valle N., Ferrer-Mayorga G., Lombardia L., Herrera M., Dominguez O., et al. MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum Mol Genet 2012, 21:2157-2165.
42. Wang W.L., Chatterjee N., Chittur S.V., Welsh J., Tenniswood M.P. Effects of 1alpha, 25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer 2011, 10:58.